Status:
COMPLETED
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for...
Eligibility Criteria
Inclusion
- Male and female outpatients 18 years of age and older
- Patients who are eligible and able to participate in the study
Exclusion
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of hypertensive encephalopathy or cerebrovascular accident.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
641 Patients enrolled
Trial Details
Trial ID
NCT00260923
Start Date
November 1 2005
End Date
November 1 2006
Last Update
November 8 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany